Citations

Clear

9383 citation(s) found for "Thomas, PS".

Single Myosin Cross-Bridge Orientation in Cardiac Papillary Muscle Detects Lever-Arm Shear Strain in Transduction
Josephson, Matthew P. , Ajtai, Katalin , Burghardt, Thomas P.

Mayo Clinic

Biochemistry | August 5, 2011 | Volume: 50 | Issue: 36 | Pages: 7809-7821

10.1021/bi2008992 | PMID 21819137 Get It

Cryptogenic Constrictive Bronchiolitis: A Clinicopathologic Study
Kraft, Monica , Mortenson, Rebecca L., Colby, Thomas V. , Waldron, James A., King, Talmadge E. , Newman, Lee Scott

Mayo Clinic

American Review of Respiratory Disease | August 3, 2011 | Volume: 148 | Issue: 4_Part_1 | Pages: 1093-1101

10.1164/ajrccm/148.4_pt_1.1093 | PMID 8214931 Get It

Abstract Four women with a chronic respiratory illness characterized by chronic cough, dyspnea, mild to severe physiologic abnormalities, relatively normal chest radiographs, and lack of response to bronchodilators or prednisone were identified and prospectively evaluated. Constrictive bronchiolitis, defined as concentric narrowing of the bronchiolar lumen, mural scarring, smooth muscle hyperplasia, and mucus stasis, was the major histologic finding on open lung biopsy in all cases. Each presented with an illness clinically distinct from asthma, connective tissue disorders, occupational or environmental lung disease, bronchiectasis, diffuse panbronchiolitis, cystic fibrosis, and emphysema. None of the patients smoked cigarettes. None had clinical evidence of a recent viral lower respiratory tract infection. The physical examinations were normal except for rales heard on chest examination in two patients. Chest radiographs showed increased bronchovascular markings in three patients. Lung function was normal in one patient, two of the patients had a reduced diffusing capacity associated with moderate hypoxemia and an obstructive ventilatory defect, and one patient exhibited a mixture of restrictive and obstructive defects. None have experienced significant progression of their disease over 1 to 5 yr of follow-up. However, complete return to normal function did not occur. We hypothesize that patients with the constellation of findings described represent a distinct and definable clinicopathologic entity and further clarifies the spectrum of “small airways disease.” Establishing the diagnosis appears important for prognostic and possibly therapeutic reasons.
Sudden-Onset Fatal Asthma: A Distinct Entity with Few Eosinophils and Relatively More Neutrophils in the Airway Submucosa?
Sur, Sanjiv , Crotty, Thomas B., Kephart, Gail M., Hyma, Bruce A., Colby, Thomas V. , Reed, Charles E., Hunt, Loren W., Gleich, Gerald J.

Mayo Clinic

American Review of Respiratory Disease | August 3, 2011 | Volume: 148 | Issue: 3 | Pages: 713-719

10.1164/ajrccm/148.3.713 | PMID 8368644 Get It

Abstract To determine the histologic differences in the airways of patients who died from sudden-onset asthma and the more common slow-onset asthma, we studied seven cases of fatal asthma. The numbers of eosinophilsand neutrophils, as well as extracellular deposition of their respective granule contents in the airway mucosa and submucosa, were determined and statistically analyzed. Four of the seven patients had slow-onset asthma attacks in which the time interval between onset of asthma and death was more than 2.5 h. In contrast, three patients had sudden-onset asthma in which the time interval between onset of asthma attack and death was less than 1 h. The four patients with slow-onset fatal asthma had more eosinophils (34.1 ± 6.3 in slow-onset; 9.7 ± 3.5 in sudden-onset; p = 0.002) and fewer neutrophils (4.8 ± 2.0 in slow-onset; 16.8 ± 5.4 in sudden-onset; p = 0.008) in the airway submucosa than did patients with sudden-onset fatal asthma. In addition, within the slow-onset fatal asthma group, eosinophils exceeded neutrophils in the airway submucosa (eosinophils > neutrophils, p = 0.002). By contrast, within the sudden-onset fatal asthma group, neutrophils exceeded eosinophils (neutrophils > eosinophils, p = 0.04). We suggest that sudden-onset fatal asthma is immunohistologically distinct from slow-onset fatal asthma and that it is characterized by a relative paucity of eosinophils in the face of an excess of neutrophils in the airway submucosa. These observations raise the possibility that the mechanism of airway inflammation as well as that of airway narrowing in sudden-onset fatal asthma may be quite distinct from those in slow-onset fatal asthma.
P4‐091: Brain MRI predictors of global and domain specific cognitive function at 10 years follow up: ARIC brain MRI study
Coker, Laura H., Burdette, Jonathan H. , Knopman, David S. , Catellier, Diane , Shibata, Dean , Mosley, Thomas H.

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_21 | Pages: No page available

10.1016/j.jalz.2011.05.2112 Get It

O1‐01‐08: Development of a genetic education and genetic risk disclosure protocol for individuals with mild cognitive impairment
Lautenbach, Denise, Karlawish, Jason , Roberts, J. Scott , Bradbury, Margaret, Uhlmann, Wendy R. , Petersen, Ronald C. , Fafowora, Tolulope, Harkins, Kristin , Zausmer, Lindsay, Green, Robert C. , Obisesan, Thomas O. , Cupples, L. Adrienne , Wood, Elisabeth McCarty

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2011.05.230 Get It

P1‐281: Multilocus genotype pattern at PICALM, CLU and APOE genes is associated with episodic memory in the NIA‐LOAD/NCRAD study
Bird, Thomas D., Farlow, Martin R. , Graff‐Radford, Neill, Wilson, Robert , Mayeux, Richard , Bennett, David A. , Boeve, Bradley F. , Diaz‐Arrastia, Ramon , Foroud, Tatiana , Goate, Alison , Graff‐Radford, Neill, Sweet, Robert A.

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2011.05.562 Get It

A middle-aged woman with nausea, weight loss, and orthostatic hypotension
Yung, Iris, Wollmann, Robert L., Singer, Wolfgang , Kelly, Thomas J. , Keegan, B. Mark

Mayo Clinic

Neurology | August 1, 2011 | Volume: 77 | Issue: 5 | Pages: 489-495

10.1212/wnl.0b013e318227b18a | PMID 21810698 Get It

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Mattsson, Niklas , Andréasson, Ulf , Batish, Sat Dev, Bernardini, Sergio , Bocchio‐Chiavetto, Luisella , Blankenstein, Marinus A. , Carrillo, María C. , Chalbot, Sonia, Coart, Els, Chiasserini, Davide , Cutler, Neal E., Dahlfors, Gunilla, Duller, Stefan, Fagan, Anne M. , Frisoni, Giovanni B. , Galimberti, Daniela , Hampel, Harald , Handberg, Aase , Heneka, Michael T. , Herskovits, A. Zara , Herukka, Sanna‐Kaisa , Humpel, Christian , Iqbal, Khalid , Kaeser, Stephan A. , Kaiser, Elmar, Kapaki, Elisabeth, Kidd, Daniel, Klivènyi, Péter , Knudsen, Cindy Soendersoe, Kummer, Markus P. , Lui, James, Lladó, Albert , Li, Qiao‐Xin , Martins, Ralph N. , Masters, Colin L. , McAuliffe, John C., Mercken, Marc, Moghekar, Abhay , Molinuevo, José Luís , Montine, Thomas J. , Nowatzke, William, O’Brien, Richard , Otto, Markus , Parnetti, Lucilla , Petersen, Ronald C. , Prvulovic, David, Reus, Herman P.M. de, Scarpini, Elio , Stefani, Alessandro , Schröder, Johannes , Shaw, Leslie M. , Skinningsrud, Anders, Skrogstad, Brith, Spreer, Annette, Trojanowski, John Q. , Tumani, Hayrettin , Umek, Robert M., Broeck, Bianca Van, Vanderstichele, Hugo, Vécsei, László , Blennow, Kaj , Frisoni, Giovanni B. , Persson, Staffan , Arai, Hiroyuki N. , Forlenza, Orestes Vicente , Galasko, Douglas , Holtzman, David M. , Hyman, Bradley T. , Jucker, Mathias , Lewczuk, Piotr , Paraskevas, George P. , Rissman, Robert A. , Soininen, Hilkka S. , Talib, Leda Leme , Teunissen, Charlotte E. , Verbeek, Marcel M. , Windisch, Manfred , Zhang, Jing , Zetterberg, Henrik , Parnetti, Lucilla , Molinuevo, José Luis , Masters, Colin L , Otto, Markus , Galimberti, Daniela

Mayo Clinic

Alzheimer's & Dementia | July 25, 2011 | Volume: 7 | Issue: 4 | Pages: 386

10.1016/j.jalz.2011.05.2243 | PMID 21784349 Get It

BackgroundThe cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)‐42, total‐tau (T‐tau), and phosphorylated‐tau (P‐tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer's Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch‐to‐batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program.MethodsThe program is open for laboratories using commercially available kits for Aβ, T‐tau, or P‐tau. CSF samples (aliquots of pooled CSF) are sent for analysis several times a year from the Clinical Neurochemistry Laboratory at the Mölndal campus of the University of Gothenburg, Sweden. Each round consists of three quality control samples.ResultsForty laboratories participated. Twenty‐six used INNOTEST enzyme‐linked immunosorbent assay kits, 14 used Luminex xMAP with the INNO‐BIA AlzBio3 kit (both measure Aβ‐(1‐42), P‐tau(181P), and T‐tau), and 5 used Meso Scale Discovery with the Aβ triplex (AβN‐42, AβN‐40, and AβN‐38) or T‐tau kits. The total coefficients of variation between the laboratories were 13% to 36%. Five laboratories analyzed the samples six times on different occasions. Within‐laboratory precisions differed considerably between biomarkers within individual laboratories.ConclusionsMeasurements of CSF AD biomarkers show large between‐laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers.
Palliation of Painful Metastatic Disease Involving Bone With Imaging-Guided Treatment: Comparison of Patients' Immediate Response to Radiofrequency Ablation and Cryoablation
Thacker, Paul G. , Callstrom, Matthew R. , Curry, Timothy B. , Mandrekar, Jayawant N. , Atwell, Thomas D. , Rubin, Joseph, Goetz, Matthew P.

Mayo Clinic

American Journal of Roentgenology | July 23, 2011 | Volume: 197 | Issue: 2 | Pages: 510-515

10.2214/ajr.10.6029 | PMID 21785102 Get It

Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia
Maurer, Matthew J. , Cerhan, James R. , Katzmann, Jerry A., Link, Brian K. , Allmer, Cristine, Call, Timothy G. , Rabe, Kari G. , Hanson, Curtis A. , Zent, Clive S. , Kay, Neil E. , Slager, Susan L. , Witzig, Thomas E. , Shanafelt, Tait D. , Chaffee, Kari G. , Maurer, Matthew , Cerhan, James R , Link, Brian K

Mayo Clinic

Blood | July 16, 2011 | Volume: 118 | Issue: 10 | Pages: 2821-2826

10.1182/blood-2011-04-349134 | PMID 21765023 Get It

AbstractFree light chains (FLCs) are the most commonly detected paraproteins in chronic lymphocytic leukemia (CLL). We examined the types of FLC abnormalities and prognostic utility of the FLC assay compared with standard prognostic biomarkers in a prospective cohort of 339 patients with newly diagnosed CLL. Three types of FLC abnormalities were identified: monoclonal elevated FLC (elevated κ and/or λ with abnormal FLC ratio), polyclonal elevated FLC (elevated κ and/or λ with normal FLC ratio), and ratio-only FLC abnormality (normal range κ and λ with abnormal FLC ratio). One hundred sixty-five patients (49%) had a FLC abnormality with approximately equal distribution among monoclonal elevation, polyclonal elevation, and ratio-only abnormality. All FLC abnormalities were associated with poor time to first treatment: monoclonal FLC (hazard ratio [HR], 4.99; 95% confidence interval [CI], 2.94-8.48), polyclonal FLC (HR, 2.40; 95% CI, 1.24-4.64), ratio-only FLC (HR, 2.57; 95% CI, 1.40-4.69). Monoclonal FLC and polyclonal FLC were associated with poor overall survival compared with patients with normal FLC. Results remained significant after adjusting for Rai stage. The FLC assay is a simple, widely available clinical test with similar prognostic utility as routinely used prognostic biomarkers for CLL. Among persons with FLC abnormalities, the type of abnormality affects prognostic significance.